The Justice Department's decision to move medical cannabis from Schedule I to Schedule III marks the first time the federal government has formally acknowledged an accepted medical use for cannabis - and for licensed operators, the business implications are real. Tax relief tied to 280E constraints, expanded research access, and shifting investor sentiment are all on the table. But in practice, the regulatory machinery that governs dispensary operations day-to-day has barely moved, and the uncertainty now layered on top of existing state frameworks may be creating as many problems as the rescheduling solves.
The 280E Question Is the One Operators Actually Care About
For years, Section 280E of the Internal Revenue Code has functioned as a structural tax penalty on cannabis businesses. Because marijuana was classified as a Schedule I controlled substance, operators could not deduct ordinary business expenses - payroll, rent, marketing, utilities - the way any other retail business can. A dispensary moving hundreds of thousands of dollars in monthly revenue could find itself paying effective tax rates that bore no resemblance to its actual net margins. The math has been brutal for single-location operators and multistate companies alike.
Rescheduling medical cannabis to Schedule III opens the door to relief from those constraints. Companies holding medical licenses stand to recover meaningful expense deductions going forward, and for vertically integrated operators running cultivation, processing, and retail under one structure, that could translate into significantly lower federal tax exposure. As Lauren Niehaus of Trulieve Cannabis Corp. put it, being taxed like a normal business allows for reinvestment - a straightforward statement that carries enormous weight for any operator who has been writing checks to the IRS that competitors in other industries simply do not.
The catch, and it is a real one: recreational cannabis remains Schedule I. Operators running combined adult-use and medical programs - which describes most dispensaries in states with dual-track licensing - are now straddling two federal classifications for the same product sold off the same shelf. That bifurcation creates compliance and accounting complexity that no one has fully mapped out yet. California moved quickly in May to propose emergency regulations allowing businesses to hold separate medical and adult-use licenses, which could help operators position themselves to capture the Schedule III benefit without entangling their recreational inventory. Other states have not moved that fast.
DEA Registration: New Requirement, Unclear Enforcement
Schedule III classification under the Controlled Substances Act brings its own obligations. Businesses that handle Schedule III substances are generally required to register with the DEA, pay annual fees, and comply with inventory tracking, reporting, and security standards set at the federal level. For cannabis operators already running seed-to-sale compliance through METRC or similar state-mandated tracking systems, the prospect of layering federal DEA registration requirements on top of existing state infrastructure is not trivial.
What makes this harder is that no one is certain whether federal enforcement of those registration requirements is actually coming, or what it will look like. Oklahoma's Bureau of Narcotics sent letters to licensed medical operators urging DEA registration and warning of potential license sanctions - but Oklahoma's own Medical Marijuana Authority said the letter came as a surprise and that the federal intent remains unclear. That is a telling detail. Two state agencies with overlapping jurisdiction over the same licensees are reading the federal signal differently, and the operators caught between them are left with no clean answer.
Companies like Spherex Labs in Colorado have opted to wait rather than register, watching for federal guidance before taking on new compliance obligations they may not yet be required to meet. That is a defensible posture - but it is also a holding pattern, not a strategy. Operators with legal and compliance teams are actively gaming out scenarios. Smaller single-state dispensaries, without those resources, are largely hoping clarity arrives before an enforcement deadline does.
States Are Holding Their Lines - For Now
State cannabis programs built their regulatory frameworks over years: licensing tiers, excise tax structures, laboratory testing requirements, compliant packaging standards, retail oversight rules, and purchase limits. None of that changes automatically because the federal classification shifted. Nevada's cannabis regulators stressed that state law still treats non-medical marijuana as Schedule I. Vermont's Cannabis Control Board chair said plainly that advising licensees is "incredibly frustrating" with a ticking clock and no federal guidance to point to. Washington and Oklahoma regulators are similarly in wait-and-see mode.
What's striking here is how much states have already out-paced federal policy. Katharine Neill Harris of Rice University's Baker Institute described the rescheduling as the federal government "catching up to what states are already doing" - which is accurate, but also points to a structural mismatch. States have functional, mature cannabis markets with testing labs issuing COAs, POS systems tracking every transaction, and compliance teams managing inventory shrinkage down to the gram. The federal government is entering that space without a clear operational framework, and states have no clean template for how federal rules will interact with their own systems.
Pending guidance from the IRS, Treasury, and DEA will matter enormously - not just for tax treatment but for how financial institutions assess the risk of serving cannabis clients. Banks have stayed largely on the sidelines because federal illegality exposes them to compliance exposure regardless of state law. Rescheduling medical cannabis does not resolve that problem wholesale, and congressional banking protection legislation remains stalled. Until that changes, dispensary operators running cash-heavy operations or relying on closed-loop cashless payment workarounds are not likely to see their banking options improve materially in the near term.
Research Access Opens, but Public Health Concerns Do Not Disappear
One concrete benefit of rescheduling is the potential to expand academic cannabis research. Schedule I status has historically created significant barriers - researchers working through federally authorized channels had limited access to commercially available products, meaning studies often did not reflect the actual potency or formulation profiles consumers encounter at retail. State university researchers could now have a cleaner path to studying products that are actually on dispensary menus, which would produce more clinically relevant data on dosing, delivery methods, and therapeutic applications.
That is a genuine development. But it does not resolve what addiction medicine specialists and public health researchers have flagged as an ongoing concern: high-potency cannabis products are widely available at retail, and consumer awareness of associated risks - including cannabis use disorder and effects on mental health - has not kept pace with market expansion. The rescheduling does not change product formulations, potency levels, or retail sales practices. Dispensary operators, particularly those running compliant retail programs with trained staff, carry a real responsibility to ensure that product education at the counter reflects both benefits and risks - not just as a regulatory obligation, but as a matter of long-term consumer trust.
The DEA hearing scheduled for late June on broader cannabis de-scheduling will be the next significant signal. But between now and any resolution of that process - which could take months or longer - operators are running businesses under a federal framework that classifies their medical inventory differently from their adult-use inventory, has not finalized registration rules, and has not resolved banking access. To put it plainly: the federal government opened a door, but the hallway behind it is still under construction.
